Pattern Group Inc.

# Signal Note: Driehaus Initiates PTRN Position **Why it matters:** Driehaus's $7.1M entry into Pattern (a precision medicine platform focused on immunology and oncology) signals conviction in the company's clinical pipeline maturation, likely ahead of near-term data readouts or partnership announcements. The position size (~2.5% of typical biotech allocation for this fund) reflects moderate conviction rather than a core holding, suggesting Driehaus is positioning selectively rather than making a major thesis bet.